Reducing Cancer Health Disparities in Detroit

总体计划摘要 P20优秀研究专项可行性与规划性研究申请表 (孢子)调查癌症健康差异将解决底特律大都市的种族差异问题 存在巨大癌症差异的独特重要的未得到服务的人群。该应用程序包括两个 科学项目专注于免疫检查点抑制剂(ICIS)的治疗，目前正在标准中使用 肺癌的护理环境、管理核心、生物医学核心、患者和社区 参与核心和发展研究计划。使用ICIS的决定在很大程度上取决于之前的 治疗反应和不完善的肿瘤生物标志物，以及免疫相关的不良事件(IrAEs)决定了 持续的治疗和最终的结果，然而关于是什么因素在种族上驱动疾病进程却知之甚少。 不同的人群。该计划的总体目标1是加速转化研究，以减少健康 肺癌预后的差异：a)针对肿瘤的特定种族免疫图谱的特征 环境和宿主遗传背景，以确定它们对应对ICIS的贡献(项目1)；和 不同种族肺癌患者报告的副作用、生活质量和irAEs的特征 并确定这些疾病的个体、行为、分子/遗传和疾病特异性决定因素 终点(项目2)。总体目标2是加强现有方案结构，以鼓励 对癌症生物学健康差异的转化研究，实现完整的P50孢子资助，以及 最终通过以下方式减少癌症健康差距：a)扩大我们的癌症生物学健康差距倡议， 促进使用KCI种族多样化人口的生物检疫剂，并为发展研究提供资金 项目；b)指导癌症健康差距方面的调查人员；c)扩大我们的社区外联和 通过强大的患者和社区参与核心(PCEC)来支持招聘工作 保留不同的研究参与者，并将研究项目的进展和结果传播到 参与者和非专业观众。这个P20应用程序将使临床、基础和人口科学家能够 将相关的、影响巨大的科学发现转化为不同患者的研究成果，以减少癌症的种族差异 结果，朝着更具种族包容性、以公平为重点的癌症精确医学方法迈进 治疗和预防。

Overall Program Summary This application for Feasibility and Planning Studies of a P20 Specialized Program of Research Excellence (SPORE) to Investigate Cancer Health Disparities will address racial disparities in metropolitan Detroit, a uniquely important underserved population where great cancer disparities exist. The application includes two scientific projects focused on treatment with immune checkpoint inhibitors (ICIs) now being used in the standard of care setting for lung cancer, an Administrative Core, a Biospecimen Core, a Patient and Community Engagement Core, and a Developmental Research Program. The decision to use ICIs relies heavily on prior treatment response and imperfect tumor biomarkers, and immune-related adverse events (irAEs) dictate continued therapy, and ultimately outcomes, yet little is known about what factors drive disease course in racially diverse populations. The Overall Aim 1 of this Program is to accelerate translational research to reduce health disparities in lung cancer outcomes by: a) characterizing race-specific immune profiles with respect to the tumor environment and host genetic background to determine their contribution to response to ICIs (Project 1); and b) characterizing patient-reported side effects, quality of life, and irAEs in a racially diverse group of lung cancer patients and identifying the individual, behavioral, molecular/genetic and disease-specific determinants of these end points (Project 2). The Overall Aim 2 is to strengthen the existing programmatic structure to encourage translational research into the biology of cancer health disparities, achieve full P50 SPORE funding, and ultimately reduce cancer health disparities by: a) expanding our Cancer Biology of Health Disparities initiative, facilitating use of biospecimens from KCI's racially diverse population, and funding Developmental Research Projects; b) mentoring investigators in cancer health disparities; and c) expanding our community outreach and engagement efforts through a robust Patient and Community Engagement Core (PCEC) to support recruitment and retention of diverse study participants and dissemination of research project progress and findings to participants and lay audiences. This P20 application will enable clinical, basic and population scientists to translate relevant, high-impact scientific discoveries in diverse patients to reduce racial disparities in cancer outcomes, moving towards a more race-inclusive, equity-focused precision medicine approach to cancer treatment and prevention.